Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival

James M. Donahue, Francis C. Nichols, Zhuo Li, David A. Schomas, Mark S. Allen, Stephen D. Cassivi, Aminah Jatoi, Robert C. Miller, Dennis A. Wigle, K. Robert Shen, Claude Deschamps

Research output: Contribution to journalArticle

172 Scopus citations

Abstract

Background: Neoadjuvant chemoradiotherapy followed by esophagogastrectomy has become the standard of care for patients with locally advanced esophageal cancer. This report analyzes our experience with this treatment approach. Methods: From January 1998 through December 2003, all patients from a single institution receiving neoadjuvant chemoradiotherapy followed by esophagogastrectomy were reviewed for operative mortality, morbidity, long-term survival, and factors affecting survival. Only patients preoperatively staged with both computed tomographic scans and endoscopic ultrasound were included. Results: There were 162 patients (142 men, 20 women), and the median age was 61 years (range, 22 to 81 years). Histopathology was adenocarcinoma in 143 patients and squamous cell in 19. Pretreatment clinical stage was II in 28 patients (17%), III in 111 (68%), and IV (M1a) in 23 (14%). Ivor Lewis esophagogastrectomy was the most common procedure, occurring in 132 patients. Operative mortality and morbidity was 4.9% and 37%, respectively. Pathologic response was complete in 42 patients (26%), near complete in 27 (17%), partial in 88 (54%), and unresectable in 5 (3%). Five-year survival for overall, complete, near complete, and partial response patients was 34%, 55%, 27%, and 27%, respectively (p = 0.013). Patients whose lymph nodes were rendered free of cancer showed improved overall and disease-free survival compared with patients having persistently positive lymph nodes (p = 0.019). Conclusions: Esophagogastrectomy after neoadjuvant chemoradiotherapy can be performed with low mortality and morbidity. Patients with complete pathologic response have significantly improved long-term survival compared with patients with near complete and partial responses. Future efforts should be directed at understanding determinants of complete responses.

Original languageEnglish (US)
Pages (from-to)392-399
Number of pages8
JournalAnnals of Thoracic Surgery
Volume87
Issue number2
DOIs
StatePublished - Feb 1 2009

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Donahue, J. M., Nichols, F. C., Li, Z., Schomas, D. A., Allen, M. S., Cassivi, S. D., Jatoi, A., Miller, R. C., Wigle, D. A., Shen, K. R., & Deschamps, C. (2009). Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced Survival. Annals of Thoracic Surgery, 87(2), 392-399. https://doi.org/10.1016/j.athoracsur.2008.11.001